Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Study’s final report confirms letrozole’s benefit for breast cancer patients

07.09.2005


Aromatase inhibitor improves survival for some patients, reduces metastasis

The complete analysis of data from an international trial of the drug letrozole (Femara) confirms earlier reports that the drug reduced the recurrence of breast cancer in women previously treated with tamoxifen. It also finds that letrozole prevents the development of metastases, even in women whose cancer had originally spread to their lymph nodes. The report appears in the September 7 issue of the Journal of the National Cancer Institute.

"The most important new findings we describe in this article are that letrozole treatment can improve the survival of women with node-positive disease and can reduce the chance that metastatic tumors will develop," says Paul E. Goss, MD, PhD, who led the investigation. At the study’s outset, Goss was with the Princess Margaret Hospital in Toronto; he now is director of Breast Cancer Research at Massachusetts General Hospital Cancer Center.



Letrozole is one of a class of drugs called aromatase inhibitors that suppress the production of estrogen. Estogen stimulates the growth of breast tumors that express the estrogen receptor, and drugs that block the production or the action of the hormone are used in the treatment of those tumors. The most widely used estrogen-blocking drug is tamoxifen, which becomes ineffective after five years of treatment, probably because tumor cells become resistant to or even dependent on the drug.

The international study, called the MA.17 trial, was conducted through the National Cancer Institute of Canada and designed to test whether letrozole could reduce tumor recurrence and increase survival in postmenopausal breast cancer patients who had completed five years of tamoxifen treatment. More than 5,000 women were enrolled and randomly assigned to receive either letrozole or a placebo for an additional five years. The study was halted in October 2003 – four years after it began – when an interim data analysis showed that the tumors of women taking letrozole were significantly less likely recur. Those results were published in the November 6, 2003 New England Journal of Medicine.

The current report analyzes all the data compiled during the MA.17 trial and confirms that the risk of recurrence was almost 5 percent lower in those receiving letrozole than in the placebo group. Women receiving the drug also had a 39 percent reduction in the risk of metastasis. While overall survival differences between the two groups were not significant, among women whose tumors had spread to their lymph nodes and those who had received tamoxifen for more than five years, letrozole was associated with significantly better overall survival.

Although participants taking letrozole did have a greater incidence of osteoporosis, there was no significant difference in reported fractures. There was also no increased risk of cardiovascular problems, which Goss says is particularly noteable. "A recent trial comparing letrozole to tamoxifen found that letrozole might be associated with heart problems. But our study, the only placebo-controlled trial of an aromatase inhibitor, found no such association. A possible explanation of the earlier study was that tamoxifen may actually protect against cardiovascular disease, which our results support."

Goss adds that current and future studies will investigate two key questions about letrozole and other aromatase inhibitors – how long treatment should continue and whether the drugs also can benefit women who previously stopped taking tamoxifen or never took that drug. One trial that has already begun will continue following the women who received letrozole throughout the MA.17 trial and re-randomize them to receive either letrozole or a placebo for an additional five years. Another study will examine tumor samples from all MA.17 trial participants to search for molecular fingerprints that might identify who would most benefit from letrozole treatment.

Emily Parker | EurekAlert!
Further information:
http://www.mgh.harvard.edu/

More articles from Studies and Analyses:

nachricht New study from the University of Halle: How climate change alters plant growth
12.01.2018 | Martin-Luther-Universität Halle-Wittenberg

nachricht Disarray in the brain
18.12.2017 | Universität zu Lübeck

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Scientists decipher key principle behind reaction of metalloenzymes

So-called pre-distorted states accelerate photochemical reactions too

What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...

Im Focus: The first precise measurement of a single molecule's effective charge

For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.

Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...

Im Focus: Paradigm shift in Paris: Encouraging an holistic view of laser machining

At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.

No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...

Im Focus: Room-temperature multiferroic thin films and their properties

Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.

Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...

Im Focus: A thermometer for the oceans

Measurement of noble gases in Antarctic ice cores

The oceans are the largest global heat reservoir. As a result of man-made global warming, the temperature in the global climate system increases; around 90% of...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

10th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Münster, 10-11 April 2018

08.01.2018 | Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

 
Latest News

Polymers Based on Boron?

18.01.2018 | Life Sciences

Bioengineered soft microfibers improve T-cell production

18.01.2018 | Life Sciences

World’s oldest known oxygen oasis discovered

18.01.2018 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>